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spontaneous dissection of the cervical carotid artery is low and likely indepen-
dent of the type of antithrombotic treatment (aspirin or anticoagulants) used.
Summary: Antithrombotic treatment in patients with spontaneous
internal carotid artery dissection (sICAD) is largely empiric. Some form of
anticoagulation is standard treatment, but whether to use aspirin or vitamin
K antagonist is unclear. The authors evaluated the incidence and predictors
of ischemic events and adverse events associated with antithrombotic ther-
apy in patients with a first sICAD. Patients were stratified to whether they
were treated with aspirin alone or anticoagulants alone for at least 3 months
after their initial diagnosis. Data were collected prospectively and analyzed
retrospectively.
Of 298 consecutive patients with sICAD (56% men; mean age, 46  10
years), 202 were treated with anticoagulants alone and 96 with aspirin alone.
The admission diagnosis was ischemic stroke in 165, transient ischemic attack
(TIA) in 37, and retinal ischemia in 8.Eight patientswere asymptomatic, and80
had local symptoms and signs, such as headache, neck pain, Horner syndrome,
or cranial nerve palsy. After 3 months, clinical follow-up was obtained by
neurologic examination in 97% of patients. The remainder had a structured
telephone interview. Outcome measures were the development of a new cere-
bral ischemic event (ischemic stroke, TIA, or retinal ischemia, symptomatic
intracranial hemorrhage) and major extracranial bleeding.
Follow-up ischemic events were rare. Ischemic stroke occurred in 0.3%,
TIA in 3.4%, and retinal ischemia in 1%. The frequency of events did not
differ significantly between patients treated with anticoagulants (5.9%, P 
.1) and those treated with aspirin (2.1%, P  .2), with an odds ratio of 3.0
(95% confidence interval, 0.7-13.5). There was also no significant difference
in the development of hemorrhagic adverse events, with a 2% incidence in
patients treated with anticoagulants and 1% in those treated with aspirin.
New ischemic events appeared to be more frequent in patients who had
sustained initial ischemic events at the time of diagnosis of their sICAD
(6.2%) then in patients who had local symptoms or asymptomatic patients
(1.1%), although this did not quite reach statistical significance (P  .06).
Comment: There are several interesting points here. The first is the
overall low frequency of new ischemic events in patients who have sICAD
irrespective of the type of antithrombotic medication used for treatment.
The second is that the frequency of new ischemic events appears to be lower
in patients with sICAD who present with local symptoms or who were
asymptomatic at presentation. Finally, the results here suggest there is no
significant difference using aspirin or warfarin to treat sICAD. Two other
recent meta-analyses also confirm this observation (Cochrane Database
Systematic Review 2003;CD000255 and Stoke 2004;35:613-4). Spontane-
ous carotid artery dissection is adequately, and perhaps best, treated with
antiplatelet therapy.
Endoscopic versus Open Vein-Graft Harvesting in Coronary-Artery
Bypass Surgery
Lopes RD, Hafley GE, Allen KB, et al. N Engl J Med 2009;361:235-44.
Conclusion: Patients undergoing harvest of the saphenous vein with
endoscopic techniques for coronary artery bypass grafting (CABG) have
higher rates of late graft failure and death compared with patients undergo-
ing open harvest of the saphenous vein.
Summary: In recent years, harvest of saphenous veins using endo-
scopic techniques has become widely prevalent in CABG surgery. Endo-
scopic techniques are also frequently used when the saphenous vein is
harvested for infrainguinal bypasses. Endoscopic vein harvest avoids the long
incisions associated with open harvesting and, at least in CABG, appears to
decrease rates of wound infection, lessen postoperative pain, and perhaps
shorten the length of hospital stay. However, the endoscopic harvesting
technique is associated with significantmanipulation of the vein as well as the
use of thermal energy close to the vein lumen.
The authors sought to determine whether endoscopic vein harvesting
had any significant effects on survival and graft patency after CABG. The
data were derived from the Project of Ex-vivo Vein Graft Engineering via
Transfection (PREVENT) IV trial, a phase 3, multicenter, randomized,
double-blind, placebo-controlled trial of ex vivo treatment of vein grafts
with an E2F transcription factor decoy in patients undergoing CABG. More
than 3000 patients were enrolled at 107 sites in 2002 and 2003. The first
2400 patients were in an angiographic cohort and were asked to return for
angiographic assessment of their coronary bypass grafts 12 to 18 months
after surgery. Although PREVENT IV failed to confirm efficacy of E2F
transcription factor in reducing vein graft failure, it did provide a large
database for subsequent analysis. The authors used this database to assess the
effects of endoscopic vein graft harvesting on vein graft failure at 12 to 18
months and on clinical outcomes at 3 years after CABG.
Endoscopic harvesting for CABG was used in 1753 patients compared
with harvesting by direct vision in 1247 patients. The surgeon determined
the method of graft harvesting, and vein graft failure was defined as a75%
diameter reduction of the graft on angiography 12 to 18 months after
surgery. Angiograms were obtained in 1817 patients and 4290 grafts.
Clinical outcomes included repeat revascularization, myocardial infarction,
and death. Rates of vein graft failure were determined in open vs endovas-cularly harvested veins, adjusting for baseline covariance. Long-term clinical
outcomes were assessed with Cox proportional hazard modeling.
Baseline characteristics were similar between patients undergoing open
vs endoscopic vein harvesting. Patients who underwent endoscopic harvest-
ing had higher rates of vein graft failure 12 to 18 months after CABG than
patients who underwent open harvesting (46.7% vs 38.0%, P  .001).
Endoscopic harvesting was also associated with higher rates of death, myo-
cardial infarction, or repeat revascularization at 3 years (20.2% vs 17.4%; ad-
justed hazard ratio [HR], 1.22; 95% confidence interval [CI], 1.01-1.47; P 
.04), death or myocardial infarction (9.3% vs 7.6%; adjustedHR, 1.38; 95%CI,
1.07-1.77; P  .01), and death (7.4% vs 5.8%; adjusted HR, 1.52; 95% CI,
1.13-2.04; P .005).
Comment: Endoscopic vein harvesting is widely believed to be associ-
ated with reduced wound-related complications, improved patient satisfac-
tion, and decreased length of hospital stay. These beliefs are based on very
short-term data. In 13 studies of endoscopic vein harvesting for coronary
surgery analyzed in a meta-analysis of 2005 (Innovations: Technology and
Techniques in Cardiothoracic and Vascular Surgery 2005;1:61-74), all but
one of the 13 studies included in the meta-analysis had data limited to only
4 to 6 weeks of follow-up. Therefore, although the current study is not
randomized for type of vein harvest, it represents a major addition to the
vascular literature. Clearly, patients prefer endoscopic harvest for CABG, the
study was not primarily designed to compare endoscopic and open vein
harvest, and better tools are now available for endoscopic harvest. Despite
this, the study should make surgeons question the continued use of endo-
vascular harvesting of saphenous veins for CABG. The data should also give
serious pause to those using endoscopic techniques to harvest the saphenous
vein for infrainguinal surgery.
Inflammation Impairs Reverse Cholesterol Transport In Vivo
McGillicuddy FC, de la Llera Moya M, Hinkle CC. Circulation 2009;19:
1135-45.
Conclusions: Attenuation of reverse cholesterol transport (RCT) and
high-density lipoprotein (HDL) efflux may contribute to atherosclerosis in
chronic inflammatory states such as obesity, type 2 diabetes, or themetabolic
syndrome, and this is independent of HDL cholesterol levels.
Summary: RCT is a process by which cholesterol in cells such as
lipid-laden foam cells is effluxed onto circulating HDL and transported back
to the liver with secretion into the bile and subsequently into feces (Circu-
lation 2006;113:2548-55). The key atheroprotective effect of HDL is
considered to be promotion of RCT. RCT is a complex process comprising
several regulated steps, among them are macrophage cholesterol efflux,
HDL cholesterol acceptor function, liver uptake of cholesterol, and choles-
terol elimination into bile and feces. Chronic atherosclerosis is marked by
inflammation and inflammation is thought to retard RCT. This impairment
of RCT by inflammation offers a potential mechanism for the association of
inflammation and atherosclerosis. The authors used a rodent macrophage-to-
feces RCT model in this study. This model tracks 3H-cholesterol from
intraperitoneally injected JE744 macrophages onto HDL in plasma and
subsequent uptake by the liver with clearance into bile or feces. They also
performed proof of concept endotoxemia studies in humans. Endotoxemia
reduced 3H-cholesteol movement from macrophage to plasma and 3H-
cholesterol associated with HDL fractions. At 48-hours, endotoxemia re-
duces bile and fecal counts of 3H-cholesterol. This was consistent with
down-regulation of hepatic expression of ABCG8 and ABCG5 as well as
ABCB11 biliary transporters. Low-dose lipopolysaccharide also reduced bile
and fecal counts of 3H-cholesterol and expression of biliary transporters.
The lipopolysaccharide effect occurred in the absence of effects on plasma or
liver counts of 3H-cholesterol.
Inflammation was then produced in healthy human volunteers by
intravenous injection of U.S. standard reference endotoxin at a dose previ-
ously shown to produce a significant inflammatory response. Blood samples
were collected, and ex vivo macrophage cholesterol efflux to acute-phase
HDL was attenuated by the endotoxemia-induced inflammatory response.
Comment: The authors have shown for the first time that acute
inflammation impairs multiple steps of RCT in vivo. They used translational
proof of concept studies to demonstrate that experimental inflammation in
humans can retard cholesterol efflux from human macrophages and reduce
HDL cholesterol acceptor function in vivo by down-regulating specific
biliary transporters of cholesterol. This is elegant translational research that
supports the concept that chronic inflammatory states such as obesity, type 2
diabetes, and the metabolic syndrome may contribute to atherosclerosis by
impairment of RCT.
The Influence of Body Mass Index on Mortality and Bleeding Among
Patients with or at High-Risk of Atherothrombotic Disease
Mak K-H, Bhatt DL, Shao M, et al. Eur Heart J 2009;30:857-65.
Conclusions: In patients with or at risk for atherothrombotic disease,
adverse cardiovascular events and bleeding complications occur more fre-
quently in those with a low body mass index (BMI).
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cardiovascular diseases, and type 2 diabetes is serving to negate the gains in
life expectancy achieved over the past decades. A meta-analysis of 40 studies
involving 250,152 patients with coronary artery disease has demonstrated
that low BMI (20.0 kg/m2) is associated with higher total and cardiovas-
cular mortality than patients with normal BMI (range, 20.0-24.9 kg/m2).
In fact, total and cardiovascular mortality was lowest among those who are
overweight but not obese, defined as a BMI between 25.0 and 29.9 kg/m2
(Lancet 2006;368:666-78).
In this study, the authors explored the relationship between BMI and
cardiovascular events in patients enrolled in the Clopidogrel for High Athero-
thrombotic Risk and Ischemic Stabilization, Management, and Avoidance
(CHARISMA) study. CHARISMA was a multinational double-blinded,
placebo-controlled, randomized, clinical trial that evaluated the efficacy of
clopidogrel in patients with atherothrombotic disease or multiple risk factors
for atherothrombotic disease who were also receiving aspirin. This is a
subanalysis of the CHARISMA data stratified for BMI. Primary end points
included cardiovascular death, myocardial infarction, or stroke as well as
all-cause mortality and bleeding complications. Follow-up was for a median
of 28 months. Varying the patients with the highest BMI quartile to those
with the lowest BMI quartile, the primary end point, cardiovascular, and
all-cause mortality all were more frequent in those in the lowest BMI
quartile. The cutoff for all cause mortality and continuous BMI was 29.9
kg/m2.
Comment: The relationship between BMI and cardiovascular out-
comes is surprisingly complex. Mortality rates in the general population are
highest among those who are overweight and underweight. In the Physi-
cians’ Health Study of 5010 middle-aged men, relative risk for all-cause
mortality was 1.4 among those who had a BMI 22.0 kg/m2 compared
with those with BMIs between 22 and 24.9 kg/m2 (Arch Intern Med
2004;164:2326-32). It may be that the relationship between obesity and
mortality differs between individuals with and without cardiovascular dis-
ease. Certainly the data do not imply obesity is protective in patients with
cardiovascular disease, but it does appear that being underweight is detri-
mental to those with cardiovascular disease.
Treatment for Blunt Cerebrovascular Injuries: Equivalence of Antico-
agulation and Antiplatelet Agents
Cothren CC, Biffl WL, Moore EE, et al. Arch Surg 2009;144:685-90.Conclusion: Treatment of patients with blunt cerebrovascular injuries
with either antithrombotic therapy or antiplatelet therapy provides equiva-
lent results in terms of overall stroke risk.
Summary: Screening protocols for blunt carotid dissection based on
mechanism of injury and patient injury patterns are widely used for evalua-
tion of patients with possible blunt cerebrovascular injuries. When such
lesions are identified, treatment has traditionally been systemic hepariniza-
tion. In recent years, however, antiplatelet agents have been an increasingly
used alternative. The authors performed a retrospective review of their
prospective database of patients with blunt cerebrovascular injuries. Data
were collected from January 1, 1997, to January 1, 2007, at a level 1 trauma
center. The main outcome measure was the incidence of stroke, stratified by
treatment with anticoagulants or antiplatelet agents. During the study
period, 422 blunt cerebrovascular injuries were identified in 301 patients
(65% men) who were a mean age of 37 years. The mean injury severity score
was 27.0. Of 282 asymptomatic blunt cerebrovascular injuries, heparin was
used to treat 192, aspirin was used in 67, and aspirin and/or clopidogrel in
23. Only one treated patient had a CVA (0.5%). There were 107 patients
who had initially asymptomatic blunt cerebrovascular injures but were
untreated, and 23 (21.5%) had a CVA. For untreated patients, the mean
time from injury to CVA was 58  10 hours. Healing of injuries (heparin,
39%; aspirin, 43%; aspirin/clopidogrel, 46%) and injury progression (12%,
10%, 15%) were equivalent between therapies.
Comment: The data indicate some form of treatment, either antico-
agulation or antiplatelet therapy, should be used for patients with asymp-
tomatic blunt cerebrovascular injuries. Obviously, a 21% risk of CVA after an
initially asymptomatic blunt cerebrovascular injury is quite high. This risk
appears to be virtually eliminated by either antiplatelet or antithrombotic
therapy. Because the patients were not randomized, the choice of therapy
was either by surgeon preference or by surgeon assessment of the relative risk
of each therapy. The authors indicate in the discussion that a bias exists in
their institution to not use antiplatelet agents in patients when there is
evidence of intracranial bleeding. Little long-term follow-up was available,
so long-term effects of antiplatelet or antithrombotic agents on healing of
the blunt cerebrovascular injuries are unknown. Prompt initiation of anti-
thrombotic treatment should follow a diagnosis of blunt cerebrovascular
injury. Choice of therapy can still be individualized based on associated
injuries and perceived risk of bleeding.
